We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Dose-dense adjuvant Doxorubicin and cyclophosphamide is not associated with frequent short-term changes in left ventricular ejection fraction.
- Authors
Morris, Patrick G; Dickler, Maura; McArthur, Heather L; Traina, Tiffany; Sugarman, Steven; Lin, Nancy; Moy, Beverly; Come, Steven; Godfrey, Laura; Nulsen, Benjamin; Chen, Carol; Steingart, Richard; Rugo, Hope; Norton, Larry; Winer, Eric; Hudis, Clifford A; Dang, Chau T
- Abstract
Doxorubicin and cyclophosphamide (AC) every 3 weeks has been associated with frequent asymptomatic declines in left ventricular ejection fraction (LVEF). Dose-dense (dd) AC followed by paclitaxel (P) is superior to the same regimen given every third week. Herein, we report the early cardiac safety of three sequential studies of ddAC alone or with bevacizumab (B).
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Vol 27, Issue 36, p6117
- ISSN
1527-7755
- Publication type
Journal Article
- DOI
10.1200/JCO.2008.20.2952